New data in hand, AstraZeneca gears up to take Duaklir into crowded U.S. COPD space
admin 7th September 2017 Uncategorised 0AstraZeneca has some positive new COPD data in hand—and it’s data that could help the company snag a new approval. In a phase 3 study, the British drugmaker’s Duaklir—a pairing of its aclidinium bromide, also known as Tudorza, and formoterol—hit its primary endpoints, outperforming each of its components individually at improving lung function in patients with moderate to severe COPD.
More: New data in hand, AstraZeneca gears up to take Duaklir into crowded U.S. COPD space
Source: fierce